Literature DB >> 17673133

Efficacy of family history in determining thrombophilia risk.

Jennifer E Dietrich1, S Paige Hertweck, Sally E Perlman.   

Abstract

STUDY
OBJECTIVE: This retrospective study sought to examine the importance of family history of cardiovascular disease (CVD) or venous thromboembolism (VTE) in predicting risk for an inherited thrombophilia. DESIGN/
METHODS: A cohort of 88 adolescent females who had a thrombophilia panel in the last three years was identified for this retrospective chart review. Family history data of CVD or VTE were collected in addition to laboratory results from the thrombophilia screen.
SETTING: Adolescent patients who had a thrombophilia screen within the last three years at University OB-GYN Associates, Louisville, KY.
RESULTS: Within the cohort (n=88), 21% of patients were found to have a documented thrombophilia. At least 47% of individuals diagnosed with thrombophilia had more than one screening abnormality. A family history of VTE was noted to have a positive predictive value (PPV) of 40% and a negative predictive value (NPV) of 88% for detection of thrombophilia. Patients with a family history of CVD alone carried a PPV of 24% and NPV of 100%. Finally, among individuals with both family history risk factors, PPV was strengthened at 52% while NPV remained unchanged.
CONCLUSIONS: Within the last decade, inherited thrombophilias have gained more clinical interest. While thrombophilia disease prevalence data is available for the adult population, there remains a paucity of data in adolescents. Our results reinforce the importance for screening adolescent females, prior to contraceptive administration, if family history risk factors exist.

Entities:  

Mesh:

Year:  2007        PMID: 17673133     DOI: 10.1016/j.jpag.2006.11.008

Source DB:  PubMed          Journal:  J Pediatr Adolesc Gynecol        ISSN: 1083-3188            Impact factor:   1.814


  1 in total

1.  Prevalence of thrombophilia in asymptomatic individuals with a family history of thrombosis.

Authors:  E Vagdatli; O Serafimidou; E Pantziarela; F Tsikopoulou; K Mitsopoulou; A Papoutsi
Journal:  Hippokratia       Date:  2013-10       Impact factor: 0.471

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.